Brookfield Asset Management Inc News - BAM.PR.K

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”...

Calidi to Effect Reverse Stock Split

Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE American:...

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new...

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors...

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101...

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new...

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting...

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

- Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor virotherapies designed improve...

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerative Medicine (CIRM) to...

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic ovarian cancer using Calidi’s licensed lead asset...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brookfield Asset Management Inc (BAM.PR.K)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BAM.PR.K News

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi to Effect Reverse Stock Split

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

BAM.PR.K Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brookfield Asset Management Inc (BAM.PR.K) News

Brookfield Asset Management Inc (BAM.PR.K)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BAM.PR.K News

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi to Effect Reverse Stock Split

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

BAM.PR.K Discussion

Your Recent History